Global Pediatric Growth Hormone Deficiency Market, By Type (Acquired, Congenital, Idiopathic), Treatment (Growth Hormone Shots, Others), Diagnosis (Blood Tests, X-Ray, CT Scan, MRI, GH Stimulation Test, Others), Symptoms (A Younger-Looking Face, Delayed Puberty, A Chubby Body Build, Impaired Hair Growth, Others), Dosage (Injection, Others), Route of Administration (Subcutaneous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2031.
Pediatric Growth Hormone Deficiency Market Analysis and Size
The rise in the prevalence of pituitary gland tumors and rising healthcare expenditure are the major factors influencing the market growth rate. Furthermore, advancements in medical technology, growing government funding, and rising initiatives by public and private organizations to spread awareness about eye diseases are the factors that will expand the pediatric growth hormone deficiency market. Other factors such as a rise in the number of endocrine disorders and an upsurge in the number of cases associated with short stature will positively impact the market growth rate. Also, a growing number of pediatric diagnostic campaigns and programs in underdeveloped nations will result in the expansion of the pediatric growth hormone deficiency market.
Data Bridge Market Research analyzes that the global pediatric growth hormone deficiency market which was USD 3.45 billion in 2023, is likely to reach USD 13.87 billion by 2031, and is expected to undergo a CAGR of 19.00% during the forecast period. “Blood tests” dominate the diagnosis segment of the market due to the growing demand for blood tests for growth hormone diagnosis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pediatric Growth Hormone Deficiency Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Acquired, Congenital, Idiopathic), Treatment (Growth Hormone Shots, Others), Diagnosis (Blood Tests, X-Ray, CT Scan, MRI, GH Stimulation Test, Others), Symptoms (A Younger-Looking Face, Delayed Puberty, A Chubby Body Build, Impaired Hair Growth, Others), Dosage (Injection, Others), Route of Administration (Subcutaneous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Merck KGaA (Germany), Novo Nordisk A/S (Denmark), Genentech, Inc. (U.S.), Ferring B.V. (Switzerland), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Biopartners GmbH (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), AnkeBio Co., Ltd. (China), GeneScience Pharmaceuticals Co., Ltd. (China), Teva Pharmaceutical Industries Ltd. (Israel), Ipsen Pharma (France), LG Chem (South Korea)
|
|
Market Opportunities
|
|
Market Definition
Growth hormone is a hormone that is required for normal growth and development. The pituitary gland, which is linked to the hypothalamus and located near the base of the brain, produces it. Growth hormone is a hormone that is delivered throughout the body by the bloodstream to assist with a variety of activities, the most significant of which is growth, especially in children. If the pituitary gland or the hypothalamus are destroyed, the amount of growth hormone produced is reduced (this is known as deficiency), resulting in a slowed rate of growth and a reduction in height in the affected kid.
Global Pediatric Growth Hormone Deficiency Market Dynamics
Drivers
- Increasing incidence of pediatric growth hormone deficiency
The rising awareness and improved diagnostic capabilities contribute to the identification of more cases of pediatric growth hormone deficiency. As a result, there is a growing patient pool, driving the demand for growth hormone therapies.
- Advancements in biotechnology and recombinant DNA technology
Innovations in biotechnology, particularly in the development of recombinant growth hormones, have led to safer and more effective treatment options for pediatric growth hormone deficiency. These advancements enhance the overall market outlook and increase the accessibility of advanced therapies.
- Rising emphasis on early diagnosis and treatment
There is an increasing emphasis on early diagnosis and intervention for pediatric health conditions, including growth hormone deficiency. Early identification allows for timely treatment, which can improve outcomes and minimize the impact of the condition on a child's growth and development.
- Growing investment for healthcare facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Strategic Collaborations and Partnerships
Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can lead to the development of innovative treatments, research initiatives, and improved diagnostic tools for pediatric growth hormone deficiency. Strategic partnerships can enhance the overall market ecosystem.
- Focus on Personalized Medicine
The trend toward personalized medicine opens opportunities for tailoring growth hormone therapies based on individual patient characteristics, genetic factors, and treatment responses. Precision medicine approaches may lead to more effective and targeted treatments, minimizing adverse effects and optimizing outcomes for pediatric patients.
Restraints
- High Cost of Treatment
Growth hormone therapies can be expensive, requiring a long-term commitment for effective treatment. The high cost of these therapies may pose a significant financial burden on families and healthcare systems, limiting accessibility for some patients.
- Adverse Effects and Safety Concerns
Some pediatric growth hormone therapies may be associated with side effects, and long-term safety concerns may influence treatment decisions. Safety considerations and potential adverse effects could impact patient compliance and contribute to hesitancy among healthcare providers and parents.
Challenges
- Diagnostic Complexity and Delayed Identification
The complexity of diagnosing pediatric growth hormone deficiency, which often requires specialized testing and careful evaluation, can lead to delays in identification. Limited routine screening may contribute to missed opportunities for early intervention and treatment.
- Limited Treatment Options for Certain Causes
Growth hormone deficiency can have various underlying causes, and treatment options may be limited or less effective in cases where the deficiency is associated with certain genetic or congenital conditions. Developing targeted therapies for specific causes presents a challenge.
This pediatric growth hormone deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pediatric growth hormone deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In February 2021, Pfizer Inc. initiated a Phase III clinical trial to evaluate the efficacy and safety of somatropin in a cohort of Japanese participants with Prader-Willi Syndrome (PWS)
- In October 2020, Erasmus Medical Center, in collaboration with Pfizer, Foundation for Prader-Willi Research, and Prader-Willi Fonds, initiated a Phase III clinical trial to assess the effect of growth hormone treatment (Genotropin) on physical and psychosocial health in adults of 30 years or older with Prader-Willi syndrome
Global Pediatric Growth Hormone Deficiency Market Scope
The pediatric growth hormone deficiency market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acquired
- Congenital
- Idiopathic
Treatment
- Growth Hormone Shots
- Others
Diagnosis
- Blood tests
- X-Ray
- CT Scan
- MRI
- GH Stimulation Test
- Others
Symptoms
- Younger-Looking Face
- Delayed Puberty
- A chubby Body Build
- Impaired Hair Growth
- Others
Dosage
- Injection
- Others
Route of administration
- Subcutaneous
- Others
End user
- Clinic
- Hospital
- Others
Global Pediatric Growth Hormone Deficiency Market Regional Analysis/Insights
The pediatric growth hormone deficiency market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, and rest of Middle East and Africa.
North America is expected to dominate the market due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to show the fastest growth during the forecast period due to the increasing research and development activities, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The pediatric growth hormone deficiency market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for pediatric growth hormone deficiency market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pediatric growth hormone deficiency market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Pediatric Growth Hormone Deficiency Market Share Analysis
The pediatric growth hormone deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pediatric growth hormone deficiency market.
Some of the major players operating in the pediatric growth hormone deficiency market are:
- Merck KGaA (Germany)
- Novo Nordisk A/S (Denmark)
- Genentech, Inc. (U.S.)
- Ferring B.V. (Switzerland)
- Eli Lilly and Company (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Biopartners GmbH (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- AnkeBio Co., Ltd. (China)
- GeneScience Pharmaceuticals Co., Ltd. (China)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Ipsen Pharma (France)
- LG Chem (South Korea)
SKU-